Aardvark Therapeutics, Inc. (AARD) intrinsic value & 10-year financials
Aardvark Therapeutics, Inc. (AARD) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 3 fiscal years revenue reached to $0, with an average return on invested capital of 121.3%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.78
- Market cap
- $74.2M
- Revenue (FY2025)
- $0
- ROIC (10-yr avg)
- 121.3%
- Free cash flow (FY2025)
- -$54.3M
AARD 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$57.6M | -$2.93 | -$54.3M | — | 223.0% |
| FY2024 | — | -$20.6M | -$1.03 | -$18.2M | — | 19.7% |
| FY2023 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Aardvark Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Aardvark Therapeutics, Inc. returns on capital have been average, hovering around 10.9% ROIC over the decade.
Aardvark Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Aardvark Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.